GlobalData on MSN4mon
FDA AdCom votes in favour of Stealth’s Barth syndrome drug
A US Food and Drug Administration (FDA) advisory committee (AdCom) has voted in support of Stealth Biotherapeutics’ ...
rheumatologyadvisor13d
FDA Extends Review of Elamipretide for Barth Syndrome
The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.